Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 29 August 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Transgene receives $15.3 Million from the Sale of Securities Held for Sale

Transgene receives $15.3 million from the sale of securities held for sale

Published 17 July 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene and NEC present New Data on TG4050 at ASCO 2023

Published 6 June 2023
Categorized as 2023, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023

Transgene immunological data demonstrating that TG4001 can induce T-cell responses

Published 5 June 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release, TG4001, TG4001

Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma

C. Ottensmeier, et al. ASCO 2023  Abstract available on the ASCO website – Download the abstract and the posterPoster Presentation

Published 26 May 2023
Categorized as 2023, Myvac, Publication, TG4050

Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting

Published 26 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Myvac, Press release, TG4001, TG4050

Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers

C. Le Tourneau, et al. ESMO 2023 Abstract available on the ESMO website – Download the abstract – Download the poster

Published 25 May 2023
Categorized as 2023, Publication, TG4001, TG4001

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001

Published 25 May 2023
Categorized as 2023, BT-001, categorie-orpheline, dates, dates, Invir.IO, Press release

Transgene provides business update and Q1 2023 financial position

business update and Q1 2023 financial position 15

Published 10 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer

First patient dosed in Phase I trial evaluating TG6050 15

Published 10 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Press release, TG6050-en

Posts pagination

Newer posts Page 1 … Page 13 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu